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BACKGROUND. Kidney cancer’s rising incidence is largely attributable to the
increased detection of small renal masses. Although surgery rates have paralleled
this incidence trend, mortality continues to rise, calling into question the neces-
sity of surgery for all patients with renal masses. Using a population-based
cohort, a competing risk analysis was performed to estimate patient survival
after surgery for kidney cancer, as a function of patient age and tumor size at
diagnosis.
METHODS. With data from the Surveillance, Epidemiology, and End Results Pro-
gram (1983–2002), a cohort was assembled of 26,618 patients with surgically trea-
ted, local-regional kidney cancer. Patients were sorted into 20 age-tumor size
categories and the numbers of patients that were alive, dead from kidney cancer,
and dead from other causes were tabulated. Poisson regression models were
fitted to obtain estimates of cancer-specific and competing-cause mortality.
RESULTS. Age-specific kidney cancer mortality was stable across all size strata
but varied inversely with tumor size. Patients with the smallest tumors enjoyed
the lowest cancer-specific mortality (5% for masses 4 cm). Competing-cause
mortality rose with increasing patient age. The estimated 5-year competing-cause
mortality for elderly subjects (70 years) was 28.2% (95% confidence interval
[CI]: 25.9%–30.8%), irrespective of tumor size.
CONCLUSIONS. Despite surgical therapy, competing-cause mortality for patients
with renal masses rises with increasing patient age. After 5 years, one-third of el-
derly patients (70 years) will die from other causes, suggesting the need for pro-
spective studies to evaluate the role of active surveillance as an initial
therapeutic approach for some small renal masses. Cancer 2007;109:1763–8.
 2007 American Cancer Society.
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T he rising incidence of kidney cancer demonstrated over the past2 decades1–4 is largely attributable to an increase in the number
of small renal masses.5 Reflecting the current treatment paradigm,6
the rising incidence has been paralleled by greater use of nephrec-
tomy.5 Despite these trends, kidney cancer mortality rates have con-
tinued their monotonous rise.5 This apparent disconnect—between
increasing treatment and increasing mortality—raises questions
regarding the necessity of surgery for all patients with small kidney
tumors.
There is growing evidence to suggest that the anticipated survival
benefit derived from the surgery for suspicious renal masses is nonu-
niform. To begin, kidney cancer is now recognized as a heterogene-
ous disease, whose histopathologic subtypes have variable natural
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histories.7,8 For this reason, it is plausible that a pro-
portion of newly diagnosed renal masses represent an
indolent form of cancer, which may not merit surgical
removal. Given the low metastatic potential of some
nonclear-cell variants7 and the slow growth rate
observed for many incidentally detected lesions,9 it is
also conceivable that age-related competing-cause
mortality might dampen the benefits of surgery for
some older patients with small renal masses. Because
the morbidity and mortality of nephrectomy are non-
trivial,10 clinicians must be able to better risk-stratify
kidney cancer patients such that those who stand to
gain the most from surgical intervention receive it. To
better inform the clinician counseling a patient with a
newly diagnosed renal mass, we estimated patient
survival after surgery for kidney cancer by performing
a competing risk analysis on a population-based
cohort with local-regional disease.
MATERIALS AND METHODS
We used data from 9 Surveillance, Epidemiology, and
End Results (SEER) registries (San Francisco-Oakland,
Connecticut, Metropolitan Detroit, Hawaii, Iowa, New
Mexico, Seattle-Puget Sound, Utah, Metropolitan
Atlanta, San Jose-Monterey, Los Angeles, Alaska) to
identify incident cases of kidney cancer based on
International Classification of Disease for Oncology,
Second Edition11 site code C64.9; histology codes
8032, 8041, 8140, 8240, 8260, 8270, 8290, 8310, 8312,
8317, 8318, 8319, 8320, 8960, 8963, and 8966; and
behavior codes 2 and 3 [for adenocarcinoma in situ
and adenocarcinoma not otherwise specified (NOS),
respectively] occurring between 1983 and 2002.
Our study cohort was limited to those patients
with local-regional disease (according to SEER’s ‘best’
staging system) who were treated with definitive sur-
gical therapy (ie, radical or partial nephrectomy and
locally ablative therapies). We ascertained the receipt
of surgical therapy based on SEER’s site-specific sur-
gery codes 10, 20, 30, 40, 50, 60, 70, and 90 (1983 to
1997). For the years 1998 to 2002, SEER added codes
for local tumor destruction (12, 13, and 14), local tu-
mor excision (22, 23, 24, 25, 26, and 27), and nephrec-
tomy with ureterectomy (80). The preceding list was
appended with these codes. Using this approach, we
identified 27,968 patients with surgically treated,
local-regional kidney cancer. We excluded 1350
patients (4.8%) with missing data for tumor size,
yielding a final study sample of 26,618 patients.
Demographic data, including age at diagnosis,
year of diagnosis, race, marital status, length of fol-
low-up, surgery type, and vital status at last contact,
were extracted. With the exception of patient age trea-
ted as a continuous variable, we treated each of these
factors as a categorical variable. Next, for analytic pur-
poses we assigned patients to 1 of 20 mutually exclu-
sive and exhaustive tumor size-age strata. Specifically,
we first assigned patients to 1 of 4 distinct tumor size
categories (<2, 2–4, >4–7, and >7 cm in size); within
each tumor size stratum we then defined 5 age cate-
gories (<50, 50–59, 60–69, 70–79, and 80 years).
Statistical Methods
The primary focus of this study was to estimate the
probability of mortality from kidney cancer or other
competing causes after surgical intervention, given a
patient’s age and tumor size at diagnosis. Therefore,
we tabulated the numbers of patients with each of the
3 outcomes of interest (alive, dead from kidney can-
cer, and dead from other causes) for each of our 20
age-tumor size combinations.
We then used separate Poisson regression models
to obtain estimates of the mortality rates from kidney
cancer and other competing medical conditions.
Finally, we applied the fitted rates of kidney cancer
death and other-cause death to the proportion of
patients still alive at the beginning of each successive
1-year follow-up interval. This provided us with esti-
mates of the proportion of patients who died from
kidney cancer and other competing causes, or who
were still alive 5 years after diagnosis. These estimates
were then plotted for each age-tumor size stratum. All
statistical tests were 2-tailed and performed at a sig-
nificance level of .05 using the SAS system (v. 9.1, SAS
Institute, Cary, NC). Institutional Review Board ap-
proval was waived for this study.
RESULTS
The characteristics of the study cohort (n ¼ 26,618)
are described in Table 1. The typical study subject
was a married, white male over age 60. Nearly all
(92%) underwent a radical nephrectomy for manage-
ment of their local-regional disease. Five years of fol-
low-up data were available for 46%, and 37% died
from kidney cancer or other causes over the study
interval.
Table 2 presents the distribution of death from
kidney cancer or competing causes stratified by tu-
mor size and age at diagnosis. Among patients with
small (4 cm) surgically treated lesions, only 5% died
from kidney cancer within 5 years. In contrast, even
with surgery 27% of patients with the largest (>7 cm)
lesions died from their disease.
Figure 1 depicts the smoothed, model-derived,
5-year cumulative mortality estimates. Age-specific
mortality from kidney cancer showed relative stability
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within each of our 4 size strata, eg, for tumors 2–4 cm
in size: those <50 years had a 5-year mortality rate of
2.8% (95% confidence interval [CI]: 2.4%–3.2%); those
50–59 years had a 5-year mortality rate of 4.6% (95%
CI: 4.1%–5.3%); those 60–69 years had a 5-year mor-
tality rate of 5.5% (95% CI: 4.8%–6.2%); those 70–79
years had a 5-year mortality rate of 6.3% (95% CI:
5.5%–7.1%); and those 80 years had a 5-year mortal-
ity rate of 7.5% (95% CI: 6.4%–8.8%). However, can-
cer-specific mortality varied inversely with tumor
size, such that patients with the smallest cancers had
the lowest predicted cancer-specific mortality (5.3%,
95% CI: 4.6%–6.1%, for those with tumors 4 cm vs
18.1%, 95% CI: 16.4%–20.0%, for those with tumors
>4 cm). In contrast, competing-cause mortality rose
with increasing patient age. For instance, the pre-
dicted, 5-year competing risk mortality for those aged
70 years and older was 28.2% (95% CI: 25.9%–30.8%),
irrespective of tumor size.
DISCUSSION
The relative benefit of definitive surgical therapy for
small renal masses (4 cm) is partially mitigated by
competing causes of mortality in older patients. For
example, nearly one-third of patients aged 70 years
and older will die from unrelated comorbid disease
within 5 years of curative surgery for their kidney can-
cer. Prior work has demonstrated a rise in the inci-
dence of these small, presumably curable, renal masses
that has been paralleled by increases in surgical ther-
TABLE 1






San Francisco 3394 (13)
Connecticut 4136 (15)
Metro Detroit 5439 (20)
Hawaii 964 (4)
Iowa 3816 (14)




Age at diagnosis  standard deviation, y 60.8  15.4













Until death 9966 (37)
Alive at 1 y 22,708 (85)
Alive at 3 y 16,631 (62)
Alive at 5 y 12,295 (46)
Treatment within 6 mo
Total nephrectomy 24,502 (92)
Partial nephrectomy 2013 (7.5)
Other surgery* 92 (0.5)
Vital status at last contact
Alive 16,652 (63)
Deceased due to renal cell 4006 (15)
Deceased due to other causes 5960 (22)
* Examples include cryosurgery and laser ablation.
TABLE 2
Five-Year Outcomes for Those Patients With Treated Local-Regional
Kidney Cancer According to Tumor Size
Age at diagnosis




Sample size (n ¼ 1291)
No. of patients deceased due to
RCC 14 18 24 20 3 79 (6)
Other causes 27 27 81 101 17 253 (20)
No. of patients alive 278 229 242 179 31 959 (74)
2–4 cm
Sample size (n ¼ 8278)
No. of patients deceased due to
RCC 31 75 141 147 52 446 (5)
Other causes 113 243 626 749 279 2010 (25)
No. of patients alive 1286 1365 1615 1294 262 5822 (70)
>4–7 cm
Sample size (n ¼ 9105)
No. of patients deceased due to
RCC 152 249 402 365 121 1289 (14)
Other causes 97 282 659 867 313 2218 (24)
No. of patients alive 1312 1449 1542 1041 254 5598 (62)
>7 cm
Sample size (n ¼ 7944)
No. of patients deceased due to
RCC 348 531 681 506 126 2192 (27)
Other causes 107 211 438 522 201 1479 (19)
No. of patients alive 1412 1065 994 650 152 4273 (54)
All tumors
Sample size (n ¼ 26,618)
No. of patients deceased due to
RCC 545 873 1248 1038 302 4006 (15)
Other causes 344 763 1804 2239 810 5960 (22)
No. of patients alive 4288 4108 4393 3164 699 16,652 (63)
RCC indicates renal cell carcinoma.
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apy.5 However, despite these 2 epidemiological trends,
kidney cancer mortality has continued its gradual
climb,5 suggesting that the current treatment algo-
rithm be revisited.
This long-standing treatment paradigm12 for pa-
tients with a suspicious renal mass generally involves
expedient surgical excision shortly after diagnosis.
The reasons for this are 2-fold. First, systemic medical
therapy and radiation regimens for kidney cancer
have been shown to be generally ineffective.13–15 Ac-
cordingly, surgery represents the best opportunity for
curative intervention. Second, patients with larger,
more advanced cancers face a dismal prognosis;16
therefore, surgery early in the disease is believed to
improve their chance of survival.
With respect to this treatment paradigm, an im-
portant underlying assumption, one not supported by
several case series,17–22 is that all small renal masses
have the universal capacity to grow and metastasize.
This assumption, however, has several possible flaws.
First, kidney cancer is not a single entity; rather, it is a
family of neoplasms with observed variants that have
distinct cytogenetic defects and histopathologic fea-
tures.8 For example, nonclear-cell sporadic types (eg,
chromophobe renal cell carcinoma) often have an in-
dolent course and a much lower metastatic potential
compared with the clear-cell variety.7 In addition to
the heterogeneous behavior of the various histologies,
kidney cancers may exhibit variable growth according
to their size. Indeed, small, suspicious tumors tend to
grow at a relatively slow pace (0.28 cm/year).9 The in-
dolent nature of these lesions is further bolstered by
autopsy data, revealing that many incidentally found,
small renal masses have less malignant potential than
clinically detected tumors.23 Given these data, it is
possible that a proportion of newly diagnosed renal
masses may not merit immediate surgical removal.
Nonetheless, in the absence of robust data regard-
ing the natural history of these small renal masses, it
is impossible to truly understand their nature. Indeed,
all large renal masses, which these data and that of
many case series24–26 suggest are clearly lethal even
after treatment, were small at one time or another.
However, the current study suggests that the relative
FIGURE 1. Five-year survival after surgical treatment for kidney cancer. Cumulative mortality for kidney cancer and all causes up to 5 years after diagnosis,
after definitive surgical therapy. White indicates survival; gray indicates nonkidney cancer mortality; black indicates kidney cancer mortality.
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benefits of surgical treatment are lowest among older
patients (eg, age 70 years) with renal masses 4 cm
in size. Thus, in this population, especially where
there is significant concurrent comorbidity, a period
of active surveillance may be warranted.
For the most part, contemporary surveillance pro-
tocols for small renal masses have been limited to
patients with substantial medical comorbidity, gener-
ally thought to be too infirm to tolerate extirpative
procedures. However, as safety of active surveillance
increases through improvements in imaging and bi-
opsy techniques, its role will likely continue to
broaden. Until this time, these data provide insight
into current clinical practice. Despite the fact that
partial nephrectomy offers equivalent local tumor
control to its radical counterpart,27,28 national trends
illustrate that the uptake of nephron-sparing surgery
for small (4 cm) renal masses has been slow.29 These
utilization trends are troubling when considered in
the context of recent findings that show radical ne-
phrectomy to be a significant risk factor for the devel-
opment of chronic kidney disease.30 The potential
consequences of kidney disease, coupled with in-
creasing competing-cause mortality with age, encour-
age a rethinking of the treatment algorithm for small
renal masses.
Our findings must be considered in the context of
several limitations. SEER does not collect data on
comorbid status, which worsens with age and affects
patient survival. However, we would argue that case-
mix adjustment in the setting of our competing risk
analysis would have been inappropriate, as our intent
was to estimate a patient’s probability of cancer-spe-
cific vs competing-cause mortality—a probability inti-
mately related to a patient’s comorbidities. In
addition, we determined the underlying cause of a
patient’s death using SEER’s cause-of-death item. The
validity of this construct, which is based on death cer-
tificate reporting, has been called into question in
several settings, specifically as it relates to issues of
race and socioeconomics.31–33 However, this approach
of measuring cause-of-death has compared favorably
with that obtained from autopsy among patients with
cancer diagnoses when tested empircally.34 Thus,
although we cannot exclude residual bias related to
coding, these data support the use of this construct in
the current context.
Conclusions
In summary, our study demonstrates that a significant
proportion of kidney cancer patients will die within 5
years of diagnosis despite definitive surgical therapy,
given the relation between competing-cause mortality
and increasing age. While we are not encouraging an
abrupt departure from the current treatment para-
digm, our data do prompt reflection on contemporary
practice patterns for kidney cancer. Further, our data
suggest the need for prospective studies to evaluate
the role of active surveillance as an initial therapeutic
approach for some small renal masses.
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